1 ABPI Vision and Narrative

Clinicians / Commissioners focused on outcomes and incentivised and remunerated on the results they achieve NICE issues Guidelines / Quality Standards to support clinicians through clear advice on best practice, including use of new technologies Industry works in partnership with the NHS to help get maximum value from the new technology (eg through joint working projects focussed on outcomes etc) Industry agrees a reimbursement level which reflects the value that a new technology offers patients and the NHS NHS has confidence that it can embrace new technologies in the knowledge they offer value for all appropriate patients – removes need to undertake value assessments/ negotiations at different levels

ABPI Vision and Narrative Vision Context ABPI Business Objectives Clinicians / Commissioners focussed on outcomes NICE issues Guidelines / Quality Standards Industry agrees a reimbursement level NHS has confidence that it can embrace new technologies Industry works in partnership with the NHS

The ABPI Vision To partner in creating an integrated healthcare system where the NHS efficiently delivers better outcomes for patients through appropriate use of innovative medicines for which industry is fairly rewarded

Context The NHS is changing, with major implications for patients, clinicians, managers and for the industry There is substantial increase in technological advances There is an increasingly elderly population UK is lagging behind Europe in health outcomes – particularly most common cancers, heart attacks and other chronic conditions There is a need to drive better value, coupled with better outcomes for patients, out of the healthcare system The PPRS has, over the last 50+ years, evolved (and continues to evolve), serving both Government and industry well The shape of the industry pipeline is an opportunity, re: innovation Access to new medicines remains an issue, as does use of these medicines by patients Expectations of corporate behaviour are concertedly changing, with both customers and society expecting greater transparency and accountability from business and from individuals (ref MPs)

ABPI Business Objectives Business PriorityObjectiveMetrics Value and Access: CDF/VBP New NHS Implementing Quality Outcomes To formulate an aligned industry position for a sustainable and holistic healthcare system that drives appropriate uptake of innovative medicines. Gain agreement on approach as part of the future PPRS Agreed value based reimbursement model Uptake metric reports Engagement in National Commissioning Board and Quality Standards Acceleration of QIPP focused joint working activities InnovationCreating a leading environment for R&D in the UK Maximising the value of our R&D investment Industry participation to ensure pilot capability clusters in Immunology & Inflammation is a success & involvement in formulation of future clusters Improved transparency, speed, quality & delivery in clinical trials based on OLS recommendations Publication of Real World Data Blueprint and Industry Guidance plus broad dissemination of UK leadership position in this area Development of and agreement to tangible steps to boost UK investment as part of 2011 Growth Review Trust & ReputationBuild industry’s role as a trusted partner in the healthcare system to create the environment in which long-term commercial and innovation objectives can be achieved Inform strategic thinking on communications and stakeholder engagement 2011 UK Industry Reputation model results Increase in positive media reporting and/or reduction in negative reporting Partnerships created with external stakeholder organisations Reversal in NHS restrictions on industry access

Vision To partner in creating a sustainable healthcare environment where the NHS efficiently delivers better outcomes for patients through appropriate use of innovative medicines for which industry is fairly rewarded